REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
REGENXBIO Inc.NASDAQ: RGNX
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 56.4% from a year ago
Deferred revenue stood at $5.92M at the end of Q1 FY2026, down 56.4% from a year earlier and down 43.4% from the prior quarter. Over 3 fiscal years it compounded at +78.8% a year.
Context
- Deferred revenue amounted to 1.7% of total assets at the end of Q1 FY2026, down 1.0 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -56.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 10.45M USD
- Year-over-year change
- +8988.7%
- 4-year CAGR
- +33.1%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.45M | +8988.7% |
| FY2024 | 2024-12-31 | 115K | -22.3% |
| FY2023 | 2023-12-31 | 148K | -91.9% |
| FY2022 | 2022-12-31 | 1.83M | -45.1% |
| FY2021 | 2021-12-31 | 3.33M | — |
Deferred Revenue vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's Mar 2026 deferred revenue of $5.92M is the highest of the 10 companies compared; the peer median is $284K.
- Its year-over-year change of -56.4% is the 4th highest of 6, against a peer median of -52.9%.
- Deferred revenue amounts to 1.7% of total assets for RGNX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.92M | -56.4% | +78.8% | 1.7% | |
| Mar 2026 | $5.21M | -32.4% | -19.3% | 9.2% | |
| Mar 2026 | $2M | -52.9% | -51.0% | 0.8% | |
| Mar 2026 | $395K | -98.1% | -70.1% | 0.2% | |
| Mar 2026 | $360K | -58.4% | -25.9% | 0.1% | |
| Jun 2026 | $284K | -31.2% | +174.5% | 0.2% | |
| Mar 2026 | $0 | — | +22.6% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding RGNX) | $284K | -52.9% | -22.6% | 0.1% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 345.21M | 96.95M | 34.52M | 57.53M | 34.47M |
| Short-term Investments | 112.23M | 267.69M | 240.74M | 177.16M | 195.6M |
| Net Receivables | 32.44M | 30.29M | 26.34M | 21.57M | 27.38M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 10.2M | 7.14M | 18.85M | 12.68M | 11.9M |
| Total Current Assets | 518.83M | 415.98M | 334.97M | 278M | 281.28M |
| Property, Plant & Equipment (Net) | 192.45M | 206.8M | 192.59M | 171.31M | 152.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 391.91M | 200.56M | 38.87M | 10.18M | 15.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 10.72M | 9.93M | 7.54M | 6.5M | 4.61M |
| Total Non-current Assets | 595.08M | 417.29M | 239M | 187.99M | 171.75M |
| Total Assets | 1.11B | 833.27M | 573.97M | 465.99M | 453.03M |
| Account Payables | 11.39M | 27.21M | 22.79M | 22.8M | 21.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 47.9M |
| Tax Payables | 11.33M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 3.33M | 1.83M | 148K | 115K | 10.45M |
| Other Current Liabilities | 57.74M | 66.67M | 86.04M | 51.92M | 20.97M |
| Total Current Liabilities | 130.47M | 130.43M | 130.27M | 103.19M | 118.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 147.41M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 18.94M |
| Other Non-current Liabilities | 134.21M | 97.84M | 49.73M | 29.01M | 638K |
| Total Non-current Liabilities | 219.13M | 186.64M | 131.96M | 103.14M | 232.2M |
| Total Liabilities | 349.61M | 317.07M | 262.23M | 206.34M | 350.3M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (161.23M) | (441.55M) | (705.05M) | (932.15M) | (1.13B) |
| Accumulated OCI | (2.57M) | (15.4M) | (4.43M) | (741K) | (687K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 764.3M | 516.2M | 311.74M | 259.65M | 102.73M |
| Total Debt | 86.68M | 94.8M | 89.29M | 82.03M | 260.52M |
| Net Debt | (258.53M) | (2.15M) | 54.77M | 24.51M | 226.05M |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.